Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy

Abstract

Aim:To make an accurate estimation of the association of ERCC1 and ERCC2 polymorphisms with osteosarcoma (OS) prognosis in Chinese population.Methods:Total 7 qualified studies with 1404 osteosarcoma patients were included. Odds ratios (OR) with 95% CIs were pooled for the survival rate in different osteosarcoma patients with ERCC1 and ERCC2 genetic polymorphisms. The heterogeneity was assessed by I2 test. Potential publication bias was assessed by Begg funnel plot and Egger linear regression test.Results:In rs11615, no significant association was found under dominant [TT+TC vs. CC: OR = 1.252, 95% CI:0.864–1.815, P = .235], recessive [TT vs. TC+CC: OR = 0.850, 95% CI: 0.695–1.030, P = .095] or allelic model [T vs. C Allele: OR = 1.219, 95% CI: 0.922–1.612, P = .165]. In rs13181, no significant association was found under dominant [AA+AC vs. CC: OR = 1.031, 95% CI: 0.800–1.329, P = .801], recessive [AA vs. AC+CC: OR = 1.005, 95% CI: 0.875, 1.154, P = .944] or allelic model [A vs. C Allele: OR = 1.009, 95% CI: 0.903–1.128, P = .870]. In rs1799793, no significant association was found under dominant [GG+GA vs. AA: OR = 1.134, 95% CI: 0.884–1.454, P = .322, recessive [GG vs. AG+AA: OR = 1.025, 95% CI: 0.881–1.192, P = .750], or allelic model [G vs. A Allele: OR = 1.046, 95% CI: 0.930–1.177, P = .450].Conclusion:This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.